The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository.
 
Noura J. Choudhury
Consulting or Advisory Role - G1 Therapeutics; Sanofi
Research Funding - Abbvie (Inst); Amgen (Inst); Harpoon therapeutics (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Wolters Kluwer (Pocket Oncology).
 
Guilherme Harada
Speakers' Bureau - AstraZeneca; Lilly; Merck; MSD; Pfizer
 
Karissa Whiting
No Relationships to Disclose
 
Ronglai Shen
No Relationships to Disclose
 
Soo-Ryum Yang
Honoraria - Prime Education
Consulting or Advisory Role - InVitae
 
David B. Solit
Stock and Other Ownership Interests - Fore Biotherapeutics; Pyramid Biosciences; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Fog Therapeutics; Fore Biotherapeutics; Pfizer; Scorpion Therapeutics; Vividion Therapeutics
 
Michael F. Berger
Consulting or Advisory Role - AstraZeneca; Lilly; PetDx
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Sara Dinapoli
No Relationships to Disclose
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - AstraZeneca; Autem Medical; Boehringer Ingelheim (I); Eisai; Exelixis; Helio Health; Incyte; Ipsen; Merck Serono; Newbridge Pharmaceuticals; Novartis (I); QED Therapeutics; Roche/Genentech; SERVIER; Yiviva
Research Funding - Arcus Ventures (Inst); AstraZeneca (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Elevar Therapeutics; Exelixis; Hepion Pharmaceuticals; Imvax; Lilly; Medivir; Merck; QED Therapeutics; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Codiak Biosciences (Inst); Debiopharm Group (Inst); Genoscience Pharma (Inst); Genoscience Pharma (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)
 
Alison M. Schram
Consulting or Advisory Role - Mersana; Merus NV; Relay Therapeutics
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Elevation Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Merus (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Surface Oncology (Inst)